CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
Reminder - Five CTS Forms will be updated on Monday September 2, 2019. Some of the forms are posted ...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...